ARCHIVES

Selumetinib Plus Docetaxel Effective in KRAS-Mutant Disease

This article is from The Cancer Letter archive.

Vol. 36 No. 1 | January 25, 2013

Download PDF Visit The Full Archive

Related Articles

Fewer, Larger RT Doses Cut Recurrence Of Early Breast Cancer, UK Study Finds

June 29, 2007

NCI Encourages IP Chemo For Stage III Ovarian Cancer

January 27, 2006

NCI Cooperative Group Clinical Trials Approved

May 29, 2009

Senate Emphasizes Balance In NCI’s Research Programs

September 24, 1993

Funding Opportunities: NCI extends Deadline for Three RFAs

July 9, 1999

Caryn Lerman Recruited By Univ. Of Pennsylvania.

September 28, 2001